Hualan Biological Vaccine Inc. (SZSE: 301207)
Health Care · Biotechnology · CN
CN¥19.88
+1.90% today · +14.6% 1Y
Hualan Biological Vaccine Inc. (SZSE: 301207) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.77B and employs 708 people.
Over the last twelve months the share price has gained 14.6%, trading between 15.43 and 27.88.
Tweenvest scores Hualan Biological Vaccine Inc. across four factors: quality 70/100, value 24/100, growth 22/100, dividend 56/100. Its strongest factor is quality.
301207 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.77B
- Revenue (TTM)
- $174.73M
- P/E
- 59.64
- EPS
- 0.33
- Dividend yield
- 8.20%
- Beta (5Y)
- 0.58
- 52-week high
- CN¥27.88
- 52-week low
- CN¥15.43
- Avg volume (3M)
- —
- Shares outstanding
- 595.00M
- Employees
- 708
- Next earnings
- —
About Hualan Biological Vaccine Inc.
Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of immunizations, including various influenza virus vaccines (such as split, quadrivalent, and H1N1 strains), recombinant hepatitis B vaccines, and meningococcal polysaccharide vaccines (including ACYW135 and Group A & C types). They also develop genetically engineered vaccines for human use. Established in 2005, Hualan Biological Bacterin Inc. is headquartered in Xinxiang, China, and previously operated as a subsidiary of Hualan Biological Engineering Inc.
- ISIN
- CNE1000058J9
- Founded
- 2005
- Listed since
- Feb 18, 2022
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals Inc.SHSE: 688319 | $1.82B | CN¥30.09 | -3.50% |
| Mesoblast LimitedASX: MSB | $1.81B | AU$2.00 | -1.96% |
| UroGen Pharma Ltd.NasdaqGM: URGN | $1.80B | $37.51 | +1.83% |
| Zenas BioPharma, Inc.NasdaqGS: ZBIO | $1.78B | $26.52 | -2.71% |
| Absci CorporationNasdaqGS: ABSI | $1.74B | $9.58 | -5.71% |
| Yantai Dongcheng Pharmaceutical Group Co.,Ltd.SZSE: 002675 | $1.71B | CN¥13.89 | +7.67% |
| Freenome, Inc.NasdaqCM: FRNM | $1.70B | $15.78 | -3.31% |
| PYC Therapeutics LimitedASX: PYC | $1.68B | AU$2.45 | -0.41% |
Figures last refreshed Oct 11, 2026.